News

Shukra Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 0.01 per equity Share (i.e. 1%) , subject to the approval of the shareholders.

Net loss of Shukra Pharmaceuticals reported to Rs 1.72 crore in the quarter ended March 2026 as against net profit of Rs 5.39 crore during the previous quarter ended March 2025. Sales declined 52.37% to Rs 6.32 crore in the quarter ended March 2026 as against Rs 13.27 crore during the previous quarter ended March 2025.For the full year,net profit rose 130.27% to Rs 22.06 crore in the year ended March 2026 as against Rs 9.58 crore during the previous year ended March 2025. Sales rose 74.07% to Rs 56.73 crore in the year ended March 2026 as against Rs 32.59 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales6.3213.27 -52 56.7332.59 74 OPM %11.0855.09 -50.6639.06 - PBDT1.398.51 -84 32.2316.34 97 PBT0.387.57 -95 28.7913.34 116 NP-1.725.39 PL 22.069.58 130 Powered by Capital Market - Live News

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 May 2026.

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 16 March 2026.Powered by Capital Market - Live News

Net profit of Shukra Pharmaceuticals rose 544.30% to Rs 20.36 crore in the quarter ended December 2025 as against Rs 3.16 crore during the previous quarter ended December 2024. Sales rose 269.85% to Rs 39.13 crore in the quarter ended December 2025 as against Rs 10.58 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales39.1310.58 270 OPM %69.3137.15 - PBDT27.664.79 477 PBT26.824.09 556 NP20.363.16 544 Powered by Capital Market - Live News